Citations
References
- Steinbach et al. 2022 Analysis of a panel-based pharmacogenomics testing program among members of a commercial and Medicare client of a pharmacy benefits manager. J Manag Care Spec Pharm. 2022;28(4):485-90
- Preventable Adverse Drug Reactions: A Focus on Drug Interactions www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm110632.htm
- www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/downloads/highlights.pdf
- www.pewinternet.org/2013/09/30/the-new-environment-for-better-health-care-decisions
- Apted and Huff, 2023 Pharmacogenomics for Improved Outcomes and Decreased Costs in Health Care
AJMC
- Swen et al. 2023. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. Volume 401, Issue 10374 p347-356
- www.pewinternet.org/2013/09/30/the-new-environment-for-better-health-care-decisions
- Fragoulakis et al.2024. Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment in Austrian kidney transplant recipients participating in the U-PGx PREPARE study. Pharmacogenomics J. 2024 Mar 18;24(2):10. doi: 10.1038/s41397-024-00330-5.
- Jarvis et al. 2022. Real-World Impact of a Pharmacogenomics-Enriched Comprehensive Medication Management Program. J Pers Med. 2022 Mar 8;12(3):421. doi: 10.3390/jpm12030421
- Perlis et al. 2018 Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study. Depress Anxiety. Vol 35 No 10.
- Thomas et al. 2021. A Hybrid Implementation-Effectiveness Randomized Trial of CYP2D6 Guided Post-operative Pain Management. Genet Med. Vol 23 No 4.